Titan Pharmaceuticals

Titan Pharmaceuticals
Traded as NASDAQ: TTNP
Industry Pharmaceuticals
Headquarters California
Key people
Sunil Bhonsle
Number of employees
13 (June 2015)
Website www.titanpharm.com

Titan Pharmaceuticals, Inc. is a California biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.

Titan's principal asset is Probuphine,[1] a slow-release implant formulation of buprenorphine hydrochloride ("buprenorphine")[2] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.[3]


  1. Probuphine®
  2. Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015.
  3. "Press Announcements - FDA approves first buprenorphine implant for treatment of opioid dependence". www.fda.gov. Retrieved 26 May 2016.

This article is issued from Wikipedia - version of the 6/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.